Danette Daniels, PHD

Danette Daniels is a Vice President of the Protein Degrader Platform at Foghorn Therapeutics developing therapeutic degraders in the areas of chromatin regulation and oncology.

She was an early leader in the field of targeted protein degradation, pioneering approaches to monitor cellular kinetics of degradation and cellular mechanism of action, as well as co-developing a new PROTAC modality. She has been an author on 58 peer-reviewed publications, the majority of which are focused on epigenetics and targeted protein degradation research. She is a member of the HESI TPD Safety Initiative and was recently elected to serve as the incoming Chair of the AACR Chemistry in Cancer Research Committee from 2026-2028. She will be a co-Chair for the inaugural “Induced Proximity Modalities and Therapeutics” Gordon Research Conference taking place in June 2026. In February of 2023, she co-founded the Women in TPD and Induced Proximity Initiative which is nearing 1000 members world-wide. This initiative highlights achievements of women in the field, organizes networking events, offers a volunteer-run mentorship program, and provides conference travel scholarships to early career scientists. Prior to Foghorn Therapeutics, she received her PhD in Biophysics at Yale University, was a postdoctoral fellow at Stanford School of Medicine, and a Group Leader at Promega Corporation.